New combo therapy aims to halt lung scarring in scleroderma

NCT ID NCT07491523

Recruiting now Disease control Sponsor: University of Patras Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with scleroderma who also have lung scarring (interstitial lung disease). It compares two treatments: a double immunosuppression regimen (rituximab plus mycophenolate mofetil) versus the same double therapy plus an anti-fibrotic drug (nintedanib or pirfenidone). The goal is to see if adding the anti-fibrotic better preserves lung function over one year. About 35 participants will be followed with regular breathing tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab, mycophenolate mofetil, and either nintedanib or pirfenidone
What this could lead to: If it works, this could point toward a better treatment combination to slow lung damage in people with scleroderma-related lung disease.
What could go wrong: This is a small, early-phase study with only 35 participants, so results may not apply to everyone. Adding an anti-fibrotic drug may also increase side effects like stomach issues or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary systemic sclerosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SSC-SYSTEMIC SCLEROSIS

Contacts and locations

Locations

University of patras
RECRUITING

Pátrai, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.